About this trial
Accurate intraoperative margin assessment in breast cancer surgery remains challenging. Current reliance on frozen section pathology is limited by prolonged processing time, sampling constraints, and resource intensity, contributing to variable outcomes.
The EndoSCell Scanner is a novel cellular-resolution fluorescence-guided imaging technology designed to address these limitations. It enables real-time, pathology-level visualization of malignant cellular features at the surgical bed. With a 3mm probe allowing comprehensive 360° margin assessment, it reduces procedural time to under five minutes and may significantly lower secondary surgery rates.
This prospective, self-controlled study aims to evaluate the accuracy of the EndoSCell Scanner for intraoperative margin assessment in patients undergoing mastectomy. Its performance will be systematically compared against both frozen section and final paraffin pathology to validate sensitivity and operational efficiency. If proven effective, this technology could become a standard adjunct tool, standardizing precision in breast cancer surgery and improving patient outcomes by enhancing surgical consistency.
Eligibility criteria
Qualifiers
Age between 18 - 70 years
Patients scheduled for breast tumor resection
Clinically or radiologically showing a solitary lesion and
(Before neoadjuvant chemotherapy) Maximum tumor diameter ≤ 5cm;
Disqualifiers
Inflammatory breast cancer;
Patients allergic to methylene blue and sodium fluorescein;
Unable to understand the trial requirements or unable to complete the study follow-up plan;
Pregnant and breastfeeding women;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
West China Hospital
Lead sponsor
Fourth People's Hospital of Sichuan Province
Collaborator